WO2018082719A1 - Uso de peptido secretagogo de la hormona de crecimiento como adyuvante vacunal - Google Patents
Uso de peptido secretagogo de la hormona de crecimiento como adyuvante vacunal Download PDFInfo
- Publication number
- WO2018082719A1 WO2018082719A1 PCT/CU2017/050006 CU2017050006W WO2018082719A1 WO 2018082719 A1 WO2018082719 A1 WO 2018082719A1 CU 2017050006 W CU2017050006 W CU 2017050006W WO 2018082719 A1 WO2018082719 A1 WO 2018082719A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- ghrp
- peptide
- vaccine
- group
- Prior art date
Links
- 101710111255 Appetite-regulating hormone Proteins 0.000 title claims description 8
- 239000012646 vaccine adjuvant Substances 0.000 title description 3
- 229940124931 vaccine adjuvant Drugs 0.000 title description 3
- 239000002671 adjuvant Substances 0.000 claims abstract description 37
- 229960005486 vaccine Drugs 0.000 claims abstract description 37
- 239000000427 antigen Substances 0.000 claims abstract description 31
- 108091007433 antigens Proteins 0.000 claims abstract description 31
- 102000036639 antigens Human genes 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 30
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 230000028993 immune response Effects 0.000 claims abstract description 8
- 239000012678 infectious agent Substances 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 6
- 230000006806 disease prevention Effects 0.000 claims abstract description 5
- 241000700605 Viruses Species 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims description 37
- 241000251468 Actinopterygii Species 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 241000271566 Aves Species 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- DLQPMEMYCIGJIM-UHFFFAOYSA-N Adjuvant peptide Natural products CC(NC(=O)CCOC1C(O)C(CO)OC(O)C1NC(=O)C)C(=O)NC(CCC(=O)O)C(=O)N DLQPMEMYCIGJIM-UHFFFAOYSA-N 0.000 claims description 4
- BSOQXXWZTUDTEL-QAQREVAFSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-QAQREVAFSA-N 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 abstract description 64
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 abstract description 61
- 244000078703 ectoparasite Species 0.000 abstract description 4
- 108010058846 Ovalbumin Proteins 0.000 description 24
- 229940092253 ovalbumin Drugs 0.000 description 24
- 230000003053 immunization Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 229940027941 immunoglobulin g Drugs 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 102000018997 Growth Hormone Human genes 0.000 description 10
- 108010051696 Growth Hormone Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000122 growth hormone Substances 0.000 description 10
- 230000028996 humoral immune response Effects 0.000 description 10
- 241000607528 Aeromonas hydrophila Species 0.000 description 9
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 9
- 238000011260 co-administration Methods 0.000 description 9
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 9
- 101800001586 Ghrelin Proteins 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 7
- 241000276707 Tilapia Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000000580 secretagogue effect Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 241001247234 Lepeophtheirus salmonis Species 0.000 description 4
- 230000000240 adjuvant effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000252233 Cyprinus carpio Species 0.000 description 3
- 241000276719 Oreochromis Species 0.000 description 3
- 102000002278 Ribosomal Proteins Human genes 0.000 description 3
- 108010000605 Ribosomal Proteins Proteins 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241000277275 Oncorhynchus mykiss Species 0.000 description 2
- 240000000528 Ricinus communis Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003324 growth hormone secretagogue Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- MGSNWNLPMHXGDD-DFWOJPNQSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2r)-6-amino-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CC=1NC=NC=1)C1=CC=CC=C1 MGSNWNLPMHXGDD-DFWOJPNQSA-N 0.000 description 1
- HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 1
- 241000191291 Abies alba Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000252231 Cyprinus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000710815 Dengue virus 2 Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101100408102 Mus musculus Phip gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000276703 Oreochromis niloticus Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241001481696 Rhipicephalus sanguineus Species 0.000 description 1
- 241000277289 Salmo salar Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004597 appetite gain Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 108010085109 glycyl-histidyl-arginyl-proline Proteins 0.000 description 1
- 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960000208 pralmorelin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to the field of molecular biology and immunology, specifically, to the development of vaccines and adjuvants therefor.
- the present invention reveals the use of a growth hormone secretagogue peptide, selected from the synthetic growth hormone releasing peptide GHRP-6 and its structural analog A233, as a molecular adjuvant for vaccines.
- GHSs Growth hormone secretagogues
- Ghrelin is the endogenous ligand of the GH secretagogue receptor (GHS-R) (Kojima et al., 1999, Nature 402: 656-660). It intervenes in multiple processes, including the regulation of energy balance, appetite, metabolic signals, among others (Dixit and Taub, 2005, Exp. Gerontol. And 40: 900-910).
- GHS in addition to stimulating GH secretion, regulate the appetite and weight gain of mammals, birds and fish (Kaiya et al, 2008, Comp. Biochem. Physiol. A 149: 109-128). They also have cardioprotective properties, by improving cardiac function variables in several in vivo studies, and inhibiting the proliferation of cancer cells (Locatelli and Rossoni, 1999, Endocrinol. 140: 4024-4031; Tivesten and Bollano, 2000, Endocrinol. 141: 60-66; Cassoni et al., 2001, J. Clin. Endocrinol. Metab. 86: 1738-1745). In addition, they are involved in processes such as inflammation and aging (Hattori, 2009, J. Clin. Endocrinol. Metab. 86: 4284-4291).
- LPS lipopolysaccharides
- ghrelin and the synthetic agonist GHRP-2 significantly inhibited the release of interleukin 6 (IL-6) and activated macrophage nitric acid, and attenuated arthritis (Granado et al., 2005 , Am. J. Physiol. Endocrinol. Metab. 288: E486-E492). Also, similar studies have been carried out that have demonstrated its anti-inflammatory effects (González-Rey et al., 2006, Gastroenterol. 130 (6), 1707-1720)
- the present invention contributes to solving the aforementioned problem, by providing an adjuvant capable of effectively enhancing the immune response towards a co-administered antigen.
- the invention aims at the use of a growth hormone secretagogue peptide, identified as SEQ ID No. 1 (GHRP-6) or SEQ ID No. 2 (A233), as a molecular adjuvant in the manufacture of a vaccine that is Used in different immunization strategies.
- said vaccine is used in the prevention of diseases caused by infectious agents.
- said diseases affect mammals, birds or fish; and infectious agents can be viruses, bacteria and ectoparasites, among others.
- the term "molecular adjuvant” refers to a substance capable of positively modulating the immune response against a vaccine antigen, producing an increase thereof.
- ghrelin or analogues thereof, as a molecular adjuvant.
- the use of ghrelin for the treatment of inflammatory diseases has been proposed (González-Rey et al., 2006, Gastroenterology 130 (6), 1707-1720; Baatar et al., 201 1, Mol Cell Endocrinol 340 : 44-58).
- the effect found as part of the present invention is unexpected, which demonstrates that the administration of GHRP-6 or A233, in combination with a vaccine antigen, stimulates the specific immune response against said antigen.
- a vaccine composition comprising a growth hormone secretagogue peptide identified as SEQ ID No. 1 (GHRP-6) or SEQ ID No. 2 (A233), at least one vaccine antigen, and pharmaceutically acceptable carriers or diluents is also described.
- the vaccine composition of the invention may comprise other compounds that act as vaccine adjuvants, and which are known to those skilled in this field of the art. Within these adjuvants are, for example, aluminum salts and oily adjuvants.
- the vaccine compositions thereof included various antigens and the GHRP-6 or A233 peptides.
- antigens that were combined with GHRP-6 or its structural analogue A233 are ovalbumin (OVA), the protein of the Dengue 2 virus capsid (C2), the phip peptide of Rhipicephalus sanguineus (Rodr ⁇ guez-Mallón et al., 2012 ; Vaccine 30: 1782-1789), the chimeric protein P0-my32 (fusion polypeptide of two Lepeophtheirus salmonis antigens) and the P0 fusion polypeptide of L. salmonis and T cell epitopes (P0-TT).
- OVA ovalbumin
- C2 Dengue 2 virus capsid
- C2 the phip peptide of Rhipicephalus sanguineus
- Vaccine 30: 1782-1789 the chimeric protein P0-my32 (fusion polypeptide of two Lepeophtheirus salmonis antigens)
- compositions were administered in mice, birds and fish, and an adjuvant effect for said secretagogues was demonstrated for the first time.
- administration of GHRP-6 or A233 combined with an antigen increases the levels of specific antibodies against said antigen, in several animal species.
- the vaccine antigen is selected from the group consisting of attenuated peptides, proteins, viruses and bacteria.
- said vaccines are administered to mammals, birds or fish.
- the vaccine composition of the invention is administrable orally or by injection.
- the sequence peptide SEQ ID No. 1 or SEQ ID No. 2 is in the vaccine composition, at a concentration of 50-600 ⁇ g / kg of formulated feed, when the vaccine is administered orally in fishes.
- the invention also discloses a method for increasing the immune response against a vaccine antigen, characterized in that an effective amount of a growth hormone secretagogue peptide, identified as SEQ ID No. 1 (GHRP-6) or SEQ ID is administered. No. 2 (A233), as a molecular adjuvant of said antigen.
- the vaccine antigen is used for the prevention of diseases caused by infectious agents.
- the sequence peptide SEQ ID No. 1 or SEQ ID No. 2 is used at 50-600 ⁇ g / kg of formulated feed, when the vaccine antigen and the adjuvant peptide are administered orally.
- peptides GHRP-6 and A233 known GH secretagogues, are obtained by chemical synthesis.
- the increase in the immune response against the antigen of interest is reversed at higher levels of protection against various infectious agents, among which are viral, bacterial and ectoparasite entities.
- FIG. 1 Antibody response in mice immunized with OVA, GHRP-6 and Freund's adjuvant, or with OVA and Freund's adjuvant.
- FIG. 1 Antibody response in mice immunized with OVA, GHRP-6 and Freund's adjuvant, by sc and ip routes (Group 3 and 4, respectively); or with OVA and Freund's adjuvant, by sc and ip routes (Groups 5 and 6, respectively).
- A titles of lgG1.
- B titles of lgG2a. The mean and standard deviation within each group are represented. ** indicates p ⁇ 0.0014; *** indicates p ⁇ 0.001.
- FIG. 1 IgG titers in mice immunized with P0 and Freund's adjuvant, or with P0, GHRP-6 and Freund's adjuvant, via ip, on day 36 of the immunization schedule. The mean and standard deviation are represented. * indicates p ⁇ 0.05.
- Figure 6. Titles of immunoglobulin M (IgM) in tilapia immunized with P0-my32 or with P0-my32 combined with GHRP-6 or with the A233 peptide, detected on day 28 of the experiment, where the immunogens were administered via ip A and C. Titles of anti-my32 IgM, B. and D. Titles of anti-PO IgM.
- IgM immunoglobulin M
- Figure 7 Percentage of tilapia with IgM titres greater than 1: 1 000, after immunization with a formulation of P0-my32 that included Montanide ISA 50 or P0-my32 that included GHRP-6 and Montanide ISA 50, in the day 28 of the experiment.
- A Percent of anti-my32 responding animals.
- B Percent of anti-PO responding animals.
- Figure 8 Response of IgM antibodies in ciaries immunized with P0-TT or with P0-TT in the presence of GHRP-6 or peptide A233, on day 28 of the experiment where the fish were immunized via ip
- Figure 9 Title of binding antibodies against Aeromonas hydrophila in common carp.
- the Y axis values represent the mean ⁇ standard error. * indicates p ⁇ 0.05; ** indicates p ⁇ 0.01.
- Group 1 Injected with PBS
- Group 2 Injected with formalin inactivated A. hydrophila cells
- Group 3 Injected with formalin inactivated A. hydrophila cells and GHRP-6 (20 ⁇ g per fish). All immunogens were combined with Montanide ISA 50.
- Example 1 Effect of co-administration of GHRP-6 on the humoral immune response against OVA.
- mice 36 female Balb / c mice were used. Six study groups of 6 animals each were separated. Of these, three groups were immunized by s.c. and the rest via i.p. In all groups, immunogens were emulsified with Freund's adjuvant.
- Group 1 Placebo (phosphate buffered saline, abbreviated PBS). Via s.c.
- Group 2 Placebo (PBS). Via i.p.
- Group 3 GHRP-6 at 10 pg / animal and OVA 5 pg / animal. Via s.c.
- Group 4 GHRP-6 at 10 pg / animal and OVA 5 pg / animal. Via i.p.
- Group 5 OVA 5 pg / animal. Via s.c.
- Group 6 OVA 5 pg / animal. Via i.p.
- FCA Freund's complete adjuvant
- FIA incomplete Freund's adjuvant
- titers of lgG1 and lgG2a were determined in sera extracted on day 36, for groups immunized with OVA in the presence or absence of GHRP-6, by s.c. and i.p. ( Figures 2A and 2B). There were no significant differences in lgG2a titres between the groups treated with GHRP-6 and those who did not receive said secretagogue, for any of the routes of administration. They were observed for lgG1, in both routes of administration, being higher in the groups vaccinated in the presence of GHRP-6.
- the lgG1 / lgG2a ratio as a reflection of the differential reactivity towards a Th2 or Th1 response, respectively, was significantly higher in the group immunized, via ip, with OVA in the presence of GHRP-6 and Freund's adjuvant, with respect to injected with OVA and Freund's adjuvant only.
- This ratio is shown in Table 1, where the data represent the average of the ratio lgG1 / lgG2a corresponding to the six animals in the group.
- Example 2 Effect of co-administration of the A233 peptide on the humoral immune response against OVA.
- mice 18 female Balb / c mice were used. The mice received 150 ⁇ of immunogen in all groups, via ip, which was administered to the mice on days 1 and 15 of the immunization schedule. Blood extractions were performed on days 0 (preimmune serum), 8, 15, 22, 36, 43 and 50. The total IgG titers present in the sera were evaluated. The animals were immunized with 5 g of OVA / animal and 10 g of A233 / animal (Group 2), or with 5 g of OVA / animal (Group 3). The control group was injected with PBS (Group 1). All immunogens were emulsified with Freund's adjuvant.
- Example 3 Effect of co-administration of GHRP-6 on the humoral immune response against the C2 antigen.
- the C2 antigen, protein of the Dengue virus capsid was obtained as a recombinant protein in Escher ⁇ chia coli, with a molecular weight of 15 kDa.
- 24 female Balb / c mice were selected from
- Group 2 10 g of C2 co-administered with 10 g of GHRP-6
- the immunogens additionally comprised aluminum hydroxide, also known as alumina.
- Immunizations were performed s.c, on days 0, 15 and 30 of the immunization schedule. Blood extractions were performed on days 0 (preimmune serum), 7, 16, 21, 28 and 35, to assess the total IgG titer.
- Figure 4 shows that, on day 28 of the immunization schedule, Group 2, treated with C2 and GHRP-6, showed a significant increase in the titer of anti-C2 IgG, compared to Group 1, treated with C2 and the aluminum hydroxide adjuvant, without GHRP-6.
- Example 4 Effect of co-administration of GHRP-6 on the humoral immune response against the P0 peptide of R. sanguineus.
- the P0 peptide is a fragment corresponding to the region of least sequence identity between the P0 ribosomal protein of the R. sanguineus tick and its host mammals.
- 24 female 6-week-old Balb / c mice were selected, which were divided into three groups of 8 mice each. Each animal received 150 ⁇ _ of immunogen, via ip, on days 1, 15 and 29 of the immunization schedule. In the first immunization FCA was used, and in the subsequent ones FIA was used.
- Group 3 100 pg of P0 co-administered with 200Mg of GHRP-6.
- Example 5 Effect of co-administration of GHRP-6 or A233 peptide on the humoral immune response against P0-my32 protein in tilapia (Oreochromis sp.).
- the chimeric protein P0-my32 was generated by the cloning of the complementary deoxyribonucleic acid (cDNA) encoding a 35 amino acid peptide of the P0 ribosomal protein of L. salmonis fused to the N-terminal end of the cDNA encoding the my32 protein of the same ectoparasite (Carpió et al., 2013; Exp. Parasite! 135: 188-199), in a vector designed for the induced expression of genes of interest in the host bacterium E. coli. This protein was produced in the bacteria and purified, as a histidine fusion protein, by affinity chromatography by metal chelates.
- cDNA complementary deoxyribonucleic acid
- Group 2 P0-my32 (1 ⁇ g / g fish weight)
- Group 3 P0-my32 (1 ⁇ g / g fish weight) co-administered with 20 ⁇ g GHRP-6
- Group 4 P0-my32 (1 ⁇ g / g fish weight co-administered with 20 ⁇ g A233
- Group 5 P0-my32 ( ⁇ ⁇ g / g fish weight) The fish in this group were fed with feed formulated with 100 ⁇ of GHRP-6 per kg of feed, daily, twice a day, for a week before and one week after the administration of my32 injections.
- the PO-TT chimeric protein is based on: a) the 35 amino acid named pPO peptide, corresponding to the least conserved region between the P0 ribosomal protein of L. salmonis and that of one of its hosts, Salmo salar and b) two epitopes of T cells, from measles virus and tetanus toxoid, respectively.
- pPO peptide 35 amino acid
- b two epitopes of T cells, from measles virus and tetanus toxoid
- Example 7 Demonstration of the adjuvant effect of GHRP-6 on the humoral immune response of common carp (Cyprinus carpió) against Aeromonas hydrophi ⁇ a bacteria.
- Group 2 Inactivated A. hydrophia cells (1 x 10 8 Colony Forming Units, abbreviated UFC) + Montanide ISA 50
- Group 3 Inactivated A. hydrophila cells (1 x 10 at CFU) and 20 pg of GHRP-6 per fish + Montanide ISA 50.
- Example 8 Controlled challenge assay in fish immunized with the inactivated Aeromonas hydrophila bacterium and the inactivated bacterium co-administered with the GHRP-6 peptide.
- Group 2 A. hydrophila cells (1 x 10 8 CFU) inactivated + Montanide ISA 50
- Group 3 A. hydrophila cells (1 x 10 8 CFU) inactivated and 20 ⁇ g GHRP-6 per fish + Montanide ISA 50.
- the fish were injected on day 0 and 14. On day 21 the challenge was made, by injection via i.p. of the lethal dose 50 (LD50) of the bacteria, and the mortality in each group was recorded for 7 days.
- the relative survival percentage (RPS) was calculated as:
- RPS (%) (% of control mortality -% of treatment mortality) / (% of control mortality) x100
- the data shows the mean and standard deviation of the maximum absorbance values determined by indirect ELISA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Fodder In General (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019522853A JP7079778B2 (ja) | 2016-11-01 | 2017-10-30 | ワクチンアジュバントとしての成長ホルモン分泌促進因子ペプチドの使用。 |
CA3041944A CA3041944A1 (en) | 2016-11-01 | 2017-10-30 | Use of a growth hormone secretagogue peptide as a vaccine adjuvant |
KR1020197015515A KR102557023B1 (ko) | 2016-11-01 | 2017-10-30 | 성장 호르몬 분비 촉진제 펩타이드의 백신 어쥬번트로의 용도 |
BR112019008624A BR112019008624A2 (pt) | 2016-11-01 | 2017-10-30 | uso de um peptídeo secretagogo do hormônio do crescimento, composição de vacina, e, método para melhorar a resposta imune contra um antígeno de vacina. |
RU2019116732A RU2768134C2 (ru) | 2016-11-01 | 2017-10-30 | Применение пептида, усиливающего секрецию соматотропного гормона, в качестве адъюванта вакцины |
EP17817647.5A EP3536338A1 (en) | 2016-11-01 | 2017-10-30 | Use of a growth hormone secretagogue peptide as a vaccine adjuvant |
MX2019005122A MX2019005122A (es) | 2016-11-01 | 2017-10-30 | Uso de peptido secretagogo de la hormona de crecimiento como adyuvante vacunal. |
US16/346,034 US11179455B2 (en) | 2016-11-01 | 2017-10-30 | Use of a growth hormone secretagogue peptide as a vaccine adjuvant |
AU2017353072A AU2017353072A1 (en) | 2016-11-01 | 2017-10-30 | Use of a growth hormone secretagogue peptide as a vaccine adjuvant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2016-0161 | 2016-11-01 | ||
CU2016000161A CU24473B1 (es) | 2016-11-01 | 2016-11-01 | Composición vacunal que comprende un péptido secretagogo de la hormona de crecimiento como adyuvante vacunal |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018082719A1 true WO2018082719A1 (es) | 2018-05-11 |
Family
ID=60765568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2017/050006 WO2018082719A1 (es) | 2016-11-01 | 2017-10-30 | Uso de peptido secretagogo de la hormona de crecimiento como adyuvante vacunal |
Country Status (12)
Country | Link |
---|---|
US (1) | US11179455B2 (es) |
EP (1) | EP3536338A1 (es) |
JP (1) | JP7079778B2 (es) |
KR (1) | KR102557023B1 (es) |
AU (1) | AU2017353072A1 (es) |
BR (1) | BR112019008624A2 (es) |
CA (1) | CA3041944A1 (es) |
CL (1) | CL2019001191A1 (es) |
CU (1) | CU24473B1 (es) |
MX (1) | MX2019005122A (es) |
RU (1) | RU2768134C2 (es) |
WO (1) | WO2018082719A1 (es) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1477181B1 (en) | 2002-01-24 | 2006-12-06 | Centro De Ingenieria Genetica Y Biotecnologia | Method of stimulating growth and resistance to diseases of aquatic organisms |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23558A1 (es) * | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
EP2446898A1 (en) * | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
-
2016
- 2016-11-01 CU CU2016000161A patent/CU24473B1/es unknown
-
2017
- 2017-10-30 AU AU2017353072A patent/AU2017353072A1/en not_active Abandoned
- 2017-10-30 BR BR112019008624A patent/BR112019008624A2/pt unknown
- 2017-10-30 US US16/346,034 patent/US11179455B2/en active Active
- 2017-10-30 WO PCT/CU2017/050006 patent/WO2018082719A1/es unknown
- 2017-10-30 EP EP17817647.5A patent/EP3536338A1/en active Pending
- 2017-10-30 RU RU2019116732A patent/RU2768134C2/ru active
- 2017-10-30 KR KR1020197015515A patent/KR102557023B1/ko active IP Right Grant
- 2017-10-30 JP JP2019522853A patent/JP7079778B2/ja active Active
- 2017-10-30 CA CA3041944A patent/CA3041944A1/en active Pending
- 2017-10-30 MX MX2019005122A patent/MX2019005122A/es unknown
-
2019
- 2019-04-30 CL CL2019001191A patent/CL2019001191A1/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1477181B1 (en) | 2002-01-24 | 2006-12-06 | Centro De Ingenieria Genetica Y Biotecnologia | Method of stimulating growth and resistance to diseases of aquatic organisms |
Non-Patent Citations (36)
Title |
---|
AWATE, FRONTIERS IN IMMUNOLOGY, vol. 4, 2013, pages 1 - 10 |
BAATAR, MOL CELL ENDOCRINOL, vol. 340, 2011, pages 44 - 58 |
BAATAR, MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 340, 2011, pages 44 - 58 |
BOWERS, ENDOCRINO!., vol. 114, 1984, pages 1537 - 45 |
CARPIO, EXP. PARASITOL, vol. 135, 2013, pages 188 - 199 |
CASSONI, J. CLIN. ENDOCRINOL. METAB., vol. 86, 2001, pages 1738 - 1745 |
DAVENPORT, PHARMACOL. REV., vol. 57, 2005, pages 541 - 546 |
DE VEER MICHAEL ET AL: "Modulation of soluble and particulate antigen transport in afferent lymph by monophosphoryl lipid A", IMMUNOLOGY AND CELL BIOLOGY, vol. 90, no. 4, April 2012 (2012-04-01), pages 404 - 410, XP009502942 * |
DIXIT, J. CLIN. INVEST., vol. 114, 2004, pages 57 - 66 |
DIXIT; TAUB, EXP. GERONTOL.Y, vol. 40, 2005, pages 900 - 910 |
GONZÁLEZ-REY, GASTROENTEROL., vol. 130, no. 6, 2006, pages 1707 - 1720 |
GONZÁLEZ-REY, GASTROENTEROLOGY, vol. 130, no. 6, 2006, pages 1707 - 1720 |
GRANADO, AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 288, 2005, pages E486 - E492 |
HARANDI, VACCINE, vol. 28, no. 12, 2010, pages 2363 - 6 |
HATTORI, J. CLIN. ENDOCRINOL. METAB., vol. 86, 2009, pages 4284 - 4291 |
KAIYA, COMP. BIOCHEM. PHYSIOL. A, vol. 149, 2008, pages 109 - 128 |
KOJIMA, NATURE, vol. 402, 1999, pages 656 - 660 |
LOCATELLI; ROSSONI, ENDOCRINOL., vol. 140, 1999, pages 4024 - 4031 |
LOFTI, KAFKAS UNIV VET FAK DERG, vol. 17, no. 6, 2011, pages 949 - 952 |
MARTINEZ REBECA ET AL: "Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus)", VACCINE, vol. 35, no. 42, 9 October 2017 (2017-10-09), pages 5722 - 5728, XP009502940 * |
MARTINEZ REBECA ET AL: "Oral administration of the growth hormone secretagogue-6 (GHRP-6) enhances growth and non-specific immune responses in tilapia (Oreochromissp.)", AQUACULTURE, ELSEVIER, AMSTERDAM, NL, vol. 452, 10 November 2015 (2015-11-10), pages 304 - 310, XP029348790, ISSN: 0044-8486, DOI: 10.1016/J.AQUACULTURE.2015.11.014 * |
MARTÍNEZ, AQUACULTURE, vol. 452, 2016, pages 304 - 310 |
MARTÍNEZ, J. OF ΣNDOCRINOL, vol. 214, 2012, pages 409 - 419 |
MELISSA L BURKE ET AL: "Innate immune pathways in afferent lymph following vaccination with poly(I:C)-containing liposomes", INNATE IMMUNITY, vol. 20, no. 5, 17 September 2013 (2013-09-17), Us, pages 501 - 510, XP055442494, ISSN: 1753-4259, DOI: 10.1177/1753425913501213 * |
PÉREZ, BRAZ J MED BIOL RES, vol. 45, no. 8, 2012, pages 681 - 92 |
R. MARTINEZ ET AL: "A novel GH secretagogue, A233, exhibits enhanced growth activity and innate immune system stimulation in teleosts fish", JOURNAL OF ENDOCRINOLOGY, vol. 214, no. 3, 1 September 2012 (2012-09-01), GB, pages 409 - 419, XP055442149, ISSN: 0022-0795, DOI: 10.1530/JOE-11-0373 * |
REBECA MARTINEZ ET AL: "A233 Peptide: A Growth Hormone Secretagogue that Promotes an Antiviral Signaling Pathway", JOURNAL OF CLINICAL & CELLULAR IMMUNOLOGY, vol. 7, no. 4, 30 August 2016 (2016-08-30), XP055442243, ISSN: 2155-9899, DOI: 10.4172/2155-9899.1000450 * |
REBECA MARTÍNEZ ET AL: "Comparative proteomic analysis of growth hormone secretagogue A233 treatment of murine macrophage cells J774A.2 indicates it has a role in antiviral innate response", BIOCHEMISTRY AND BIOPHYSICS REPORTS, vol. 5, 1 March 2016 (2016-03-01), pages 379 - 387, XP055442393, ISSN: 2405-5808, DOI: 10.1016/j.bbrep.2016.01.008 * |
RODRÍGUEZ-MALLÓN, VACCINE, vol. 30, 2012, pages 1782 - 1789 |
SMITH, TRENDS ENDOCRINOL. METAB., vol. 16, 2005, pages 436 - 442 |
TANNENBAUM; BOWERS, ENDOCRINE, vol. 14, 2001, pages 21 - 27 |
TAUB, VITAM. HORM., vol. 77, 2007, pages 325 - 346 |
TIVESTEN; BOLLANO, ENDOCRINOL., vol. 141, 2000, pages 60 - 66 |
YADA, ENDOCRINOL., vol. 152, 2007, pages 353 - 358 |
YADA, ENDOCRINOL., vol. 189, 2006, pages 57 - 65 |
YIN ET AL., FISH & SHELLFISH IMMUNOL., vol. 6, 1996, pages 57 - 69 |
Also Published As
Publication number | Publication date |
---|---|
RU2768134C2 (ru) | 2022-03-23 |
US11179455B2 (en) | 2021-11-23 |
JP7079778B2 (ja) | 2022-06-02 |
US20200353065A1 (en) | 2020-11-12 |
KR102557023B1 (ko) | 2023-07-19 |
RU2019116732A (ru) | 2020-12-03 |
CU24473B1 (es) | 2020-02-04 |
EP3536338A1 (en) | 2019-09-11 |
MX2019005122A (es) | 2019-06-20 |
RU2019116732A3 (es) | 2021-02-25 |
CU20160161A7 (es) | 2018-06-05 |
AU2017353072A1 (en) | 2019-05-23 |
CL2019001191A1 (es) | 2019-10-04 |
JP2020500842A (ja) | 2020-01-16 |
CA3041944A1 (en) | 2018-05-11 |
BR112019008624A2 (pt) | 2019-07-09 |
KR20190079648A (ko) | 2019-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8257713B2 (en) | Vaccine | |
Hynes et al. | Immune response of Atlantic salmon to recombinant flagellin | |
ES2968398T3 (es) | Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria | |
EP1768696B1 (en) | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus | |
JP2003535906A (ja) | アジュバントの組み合わせとしてのqs−21及びil−12 | |
US11382962B2 (en) | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same | |
WO2007146359A2 (en) | Sea lice antigen vaccines | |
WO2018082719A1 (es) | Uso de peptido secretagogo de la hormona de crecimiento como adyuvante vacunal | |
CA2844898C (en) | Use of the pacap as a molecular adjuvant for vaccines | |
WO2013171548A2 (es) | Peptidos que inducen en peces una respuesta inmune contra copepodos y/o un escudo mucoso, vacunas, usos y métodos para modular la respuesta inmune de un pez y/o inducir la generación de un escudo mucoso | |
Jun et al. | Anti-recombinant gametocyte 56 protein IgY protected chickens from homologous coccidian infection | |
EP4382533A1 (en) | Protein nanopellets for fish or teleost and crustacean vaccination | |
WO2020009216A1 (ja) | SseJタンパク質を用いたサルモネラワクチン | |
Piganelli | Development of enteric protected vaccines for aquaculture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17817647 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3041944 Country of ref document: CA Ref document number: 2019522853 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019008624 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017353072 Country of ref document: AU Date of ref document: 20171030 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197015515 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017817647 Country of ref document: EP Effective date: 20190603 |
|
ENP | Entry into the national phase |
Ref document number: 112019008624 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190429 |